Section Arrow
MRSN.NASDAQ
- Mersana Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/06/03 23:33 EDT
Last
 0.3488
-0.0251 (-6.71%)
Day High 
0.3833 
Prev. Close
0.3739 
1-M High
0.424 
Volume 
3.48M 
Bid
0.3421
Ask
0.3555
Day Low
0.3381 
Open
0.38 
1-M Low
0.303 
Market Cap 
46.60M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.37 
20-SMA 0.35 
50-SMA 0.36 
52-W High 2.83 
52-W Low 0.2589 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.59/-1.82
Enterprise Value
58.84M
Balance Sheet
Book Value Per Share
-0.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
40.50M
Operating Revenue Per Share
0.33
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed:2025/06/03 23:33 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.